Free Trial
NASDAQ:CNTB

Connect Biopharma (CNTB) Stock Price, News & Analysis

Connect Biopharma logo
$1.83 +0.10 (+5.78%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.84 +0.01 (+0.82%)
As of 08/22/2025 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Connect Biopharma Stock (NASDAQ:CNTB)

Key Stats

Today's Range
$1.71
$1.84
50-Day Range
$0.95
$2.38
52-Week Range
$0.51
$2.86
Volume
121,848 shs
Average Volume
159,527 shs
Market Capitalization
$101.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Strong Buy

Company Overview

Connect Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

CNTB MarketRank™: 

Connect Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 292nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Connect Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Connect Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Connect Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Connect Biopharma are expected to decrease in the coming year, from ($0.22) to ($0.32) per share.

  • Price to Book Value per Share Ratio

    Connect Biopharma has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Connect Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.08% of the float of Connect Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Connect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Connect Biopharma has recently decreased by 43.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Connect Biopharma does not currently pay a dividend.

  • Dividend Growth

    Connect Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.08% of the float of Connect Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Connect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Connect Biopharma has recently decreased by 43.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Connect Biopharma has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Connect Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for CNTB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Connect Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Connect Biopharma's insider trading history.
Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CNTB Stock News Headlines

Equities Analysts Offer Predictions for CNTB Q3 Earnings
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.tc pixel
Connect Biopharma Posts Q2 Revenue Drop
See More Headlines

CNTB Stock Analysis - Frequently Asked Questions

Connect Biopharma's stock was trading at $1.38 at the beginning of the year. Since then, CNTB stock has increased by 32.6% and is now trading at $1.83.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) posted its earnings results on Thursday, May, 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.07.

Connect Biopharma (CNTB) raised $150 million in an initial public offering on Friday, March 19th 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

Connect Biopharma's top institutional shareholders include BML Capital Management LLC (3.28%), AlphaCore Capital LLC (0.14%), Koa Wealth Management LLC (0.09%) and XTX Topco Ltd (0.05%).

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
5/15/2025
Today
8/24/2025
Next Earnings (Estimated)
9/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNTB
CIK
1835268
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$7.00
Potential Upside/Downside
+282.5%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
7.24
Quick Ratio
7.24

Sales & Book Value

Annual Sales
$26.03 million
Price / Sales
3.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.28 per share
Price / Book
1.43

Miscellaneous

Outstanding Shares
55,720,000
Free Float
43,129,000
Market Cap
$101.97 million
Optionable
Optionable
Beta
-0.09
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:CNTB) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners